First, this study was the first to evaluate sRAGE as a risk marker for pancreatic cancer in women and to evaluate chemokines MCP1 and PAI‐1 and pancreatic cancer risk in any cohort. This evidence concerns the gene CCL2 and pancreatic neoplasm.